Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients

Immune checkpoint inhibition represents an important therapeutic option for advanced melanoma patients. Results from clinical studies have shown that treatment with the <i>PD-1</i> inhibitors Pembrolizumab and Nivolumab provides improved response and survival rates. Moreover, combining N...

Full description

Bibliographic Details
Main Authors: Anne Schaefer, Christos Sachpekidis, Francesca Diella, Anja Doerks, Anne-Sophie Kratz, Christian Meisel, David B. Jackson, Theodoros G. Soldatos
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
Pembrolizumab
melanoma
immune checkpoint inhibitors
adverse events
FDA’s Adverse Event Reporting System (FAERS)
VigiBase
Online Access:https://www.mdpi.com/2072-6694/12/4/1008

Internet

https://www.mdpi.com/2072-6694/12/4/1008

Similar Items